Fisetin, in combination with radiation, showed anti-proliferative effects in liver cancer cells and overcame radioresistance through the activation of the PERK signaling pathway and the inhibition of the EMT phenomenon in radio-resistant liver cancer cells. The gene discussed is EIF2AK3; the disease is liver cancer.